New Novartis Biotech to Purchase AstraZeneca Plant

Swiss biotech manufacturer, AveXis, has announced that it has signed an agreement to purchase AstraZeneca’s closed 692,000 sq.ft. manufacturing plant in Longmont.  The biotech firm, part of the Novartis family, has indicated that it will hire back the bulk of former AstraZeneca employees from the Longmont facility in the process.

The move comes just three months after AstraZeneca stated that it would be closing both its Boulder and Longmont plants and laying off its 200 employees.

In September 2015, AstraZeneca purchased the Amgen manufacturing facility in Boulder that had been in operation for almost 20 years.   AstraZeneca then purchased the 70 acre Amgen facility in Longmont in 2016  to support its Boulder operations.  The future of the Boulder plant is not known.

Novartis purchased Illinois-based AveXis, a clinic-stage gene therapy company, for $8.7 billion in 2018.

Register for the Farewell State-of-the-State

JOIN US at the next State-of-the-State breakfast Tuesday April 23.

REGISTER HERE.

INTERESTED IN SPONSORING?

 

Contact Alexis Hertel at  

ahertel@hmo-info.com

(303) 322-2228

Thank You For Your Loyalty.

HCCA, publishers of the Colorado Managed Care Newsletter, began reporting on the financing of healthcare in Colorado in December of 1983. As we begin our 35th year, we are grateful for the opportunity to be one of your sources of information in this ever-changing, healthcare market.